Evinature Overview
Evinature was founded on the nexus of two medical philosophies. By bridging the gap between modern and traditional medicine, we’re able to provide more patients with safe and natural remedies that are embraced by the medical community. We believe it’s time for healthcare to prioritize patient global accessibility to accurate medical assessments and affordable treatments. No patents, no trends, no misinformation. We simply develop, test, prove, then give back to the community. Tailored Protocols: No two bodies are the same, which is why we provide evidence-based protocols that address each patient’s condition and state of severity so we can precisely target your individual needs and improve long-term results. Guided Care: Regular online follow-ups enable precise adjustments to your protocol so we can address your changing needs throughout treatment. And to ease the way, we also provide complementary clinic support to guide you through the entire process. Labs: We’re constantly refining our products through ongoing research and collaborations with over 20 leading medical centers in the U.S, enabling the further development of effective neutraceuticals that are accessible to patients worldwide. Evidence: Evinature prioritizes evidence above the trends. We are caregivers by profession, and therefore emphasize product quality and scientific integrity above all else, exclusively distributing products that have passed the golden standard of clinical trials. By the Patient for the Patient: Patients are the greatest untapped resource in healthcare, which is why we’ve developed a research database founded on their invaluable experience. At Evinature, each patient contributes to the community simply by taking the assessment. This allows us to constantly expand our research and keep the community updated with vital news and information.
Latest News
growth-positive
New CurQD Research Makes Waves at USA's Largest GI Conference | Evinature
At the Digestive Disease Week (DDW) 2025 conference, Evinature showcased its CurQD® Protocol, a clinically validated nutraceutical for treating IBD, including Ulcerative Colitis and Crohn’s Disease. The protocol was highlighted for its cost-effectiveness compared to FDA-approved therapies and does not require FDA approval to reach patients. Evinatures co-founders engaged with medical institutions and researchers, reinforcing CurQD®s reputation as a viable treatment option. The conference facilitated discussions with pharma representatives and gastroenterology leaders, emphasizing CurQD®s potential to make gut healthcare more affordable. Evinature aims to expand CurQD®s reach through clinical partnerships and global recognition.
Product StagePartners
CurQD Protocol by Evinature Highlighted at Crohn’s & Colitis Congress 2025
growth-positive
Tal’s Journey: Overcoming 16 Years of IBD - evinature
The article narrates the story of Tal, who battled ulcerative colitis for nearly two decades. Despite trying various medications and biological treatments, he found no lasting relief until he discovered the CurQD® Protocol from Evinature. This natural treatment transformed his life, leading to full remission within weeks. Tals story highlights the potential of natural solutions in managing chronic conditions like ulcerative colitis. The CurQD® Protocol allowed him to regain his health and return to his active lifestyle, serving as an inspiration for others seeking alternative treatments.
Product Stage
growth-positive
Evinature Co-Founder Dr. Prof. Shomron Ben Horin, MD Presents Groundbreaking CurQD® Research at GEDII Conference in Portugal
At the GEDII annual IBD conference, Evinatures co-founder, Dr. Prof. Shomron Ben Horin, presented findings from recent placebo-controlled trials on CurQD®, a natural supplement for gastrointestinal conditions. The conference, attended by leading gastroenterologists and researchers, highlighted CurQD®s potential to complement conventional therapies. Dr. Ben Horin emphasized the importance of global collaboration in advancing IBD treatment and noted the growing interest in integrating natural, evidence-based solutions into clinical practice. Evinature remains committed to pioneering natural, science-backed solutions for gastrointestinal health, with CurQD® at the forefront of innovation.
growth-positive
Lucy’s Journey to Remission: How CurQD Transformed Her Life - evinature
The article highlights Lucys journey to remission from Crohns and ulcerative colitis using Evinatures CurQD® Protocol. After years of struggling with her condition and trying various treatments, Lucy found success with CurQD®, which significantly improved her quality of life. She praises the product for its effectiveness and affordability, and appreciates the support and community provided by Evinature. Lucys story underscores the transformative potential of CurQD® and offers hope to others seeking natural healing paths. Evinatures personalized approach and community support are also emphasized as key factors in her successful remission.
| Sector | Health Tech & Life Sciences |
Funding
| Total funding | $6.5M |
| Last funding | $2.5M |
| Stage | Seed |
| Rounds | 3 |
| Investors | 1 |
Team Members
18
Employees: 11-50
Web & Social Links
| Website | evinature.com/ |
Locations
HaMelacha St 3, Binyamina-Giv'at Ada, Israel
Photos & Videos
12 item(s)
Evinature Business
Business models
B2B, B2B2C, B2C
Product stage
Released
Employees
11-50
Sector
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & DevelopmentTarget Customer
Healthcare & Life SciencesHealthcarePatientsCore Technology
BiologicalsHerbalsTags (9)
supplementsmedical-productsmental-healthpharmaceuticalsgastroenterologytreatmentsinflammatory-diseasescrohn's-diseasenutraceuticalsUse Cases
Kaleigh's Evinature StoryMegan's Evinature StoryLJ's Evinature StorySharon's Son's Evinature StoryShahar's Evinature StoryDevang's Evinature StoryElizabeth's Evinature StoryHeidi's Evinature StoryTal's Evinature StoryMoses's Evinature StoryLucy's Evinature StoryRodrigo's Evinature StoryTrish's Evinature StoryKatie's Evinature StoryDiane's Evinature StoryYazmin's Evinature StoryMiroslava's Evinature StoryHannah's Evinature StoryKaeleigh's Evinature StoryAlex's Evinature StoryAmy's Evinature StoryAlexa's Evinature StoryCarly's Evinature StorySheryl's Evinature StoryNoah's Evinature StoryJosh's Evinature StoryKirsten's Evinature StoryKeith's Evinature StoryTomer's Evinature StoryAlmog and His Mother's Evinature StoryGeographic Markets
North AmericaIsraelBahamasBosnia and HerzegovinaPolandHong KongSouth AfricaWestern EuropeAustraliaTurkeySingaporeHondurasCyprusColombiaUnited Arab EmiratesNew ZealandSouth KoreaRomaniaEvinature Financials
$6.5M
Total funding
—
Capital raised
$2.5M
Last funding
Seed
Funding stage
3
Total rounds
1
Investors
Evinature Lifecycle
Evinature News
38 articles
growth-positive
New CurQD Research Makes Waves at USA's Largest GI Conference | Evinature
At the Digestive Disease Week (DDW) 2025 conference, Evinature showcased its CurQD® Protocol, a clinically validated nutraceutical for treating IBD, including Ulcerative Colitis and Crohn’s Disease. The protocol was highlighted for its cost-effectiveness compared to FDA-approved therapies and does not require FDA approval to reach patients. Evinatures co-founders engaged with medical institutions and researchers, reinforcing CurQD®s reputation as a viable treatment option. The conference facilitated discussions with pharma representatives and gastroenterology leaders, emphasizing CurQD®s potential to make gut healthcare more affordable. Evinature aims to expand CurQD®s reach through clinical partnerships and global recognition.
Product StagePartners
CurQD Protocol by Evinature Highlighted at Crohn’s & Colitis Congress 2025
growth-positive
Tal’s Journey: Overcoming 16 Years of IBD - evinature
The article narrates the story of Tal, who battled ulcerative colitis for nearly two decades. Despite trying various medications and biological treatments, he found no lasting relief until he discovered the CurQD® Protocol from Evinature. This natural treatment transformed his life, leading to full remission within weeks. Tals story highlights the potential of natural solutions in managing chronic conditions like ulcerative colitis. The CurQD® Protocol allowed him to regain his health and return to his active lifestyle, serving as an inspiration for others seeking alternative treatments.
Product Stage
growth-positive
Evinature Co-Founder Dr. Prof. Shomron Ben Horin, MD Presents Groundbreaking CurQD® Research at GEDII Conference in Portugal
At the GEDII annual IBD conference, Evinatures co-founder, Dr. Prof. Shomron Ben Horin, presented findings from recent placebo-controlled trials on CurQD®, a natural supplement for gastrointestinal conditions. The conference, attended by leading gastroenterologists and researchers, highlighted CurQD®s potential to complement conventional therapies. Dr. Ben Horin emphasized the importance of global collaboration in advancing IBD treatment and noted the growing interest in integrating natural, evidence-based solutions into clinical practice. Evinature remains committed to pioneering natural, science-backed solutions for gastrointestinal health, with CurQD® at the forefront of innovation.
growth-positive
Lucy’s Journey to Remission: How CurQD Transformed Her Life - evinature
The article highlights Lucys journey to remission from Crohns and ulcerative colitis using Evinatures CurQD® Protocol. After years of struggling with her condition and trying various treatments, Lucy found success with CurQD®, which significantly improved her quality of life. She praises the product for its effectiveness and affordability, and appreciates the support and community provided by Evinature. Lucys story underscores the transformative potential of CurQD® and offers hope to others seeking natural healing paths. Evinatures personalized approach and community support are also emphasized as key factors in her successful remission.
growth-positive
Evinature Co-Founder Nir Salomon, ChB, Shares Insights in Live Interview with Leading IBD Advocate
Evinatures co-founder, Nir Salomon, participated in an Instagram Live interview with Liam Robertson, discussing the companys origins, the science behind their CurQD® Protocol, and future plans for gut health solutions. The conversation covered the clinical trials of CurQD®, potential insurance coverage in the U.S. and UK, and other products like DivertX and Exhale. Evinature aims to make clinically-proven, natural gut health solutions accessible, reshaping the standard of care for IBD and related conditions. The company is focused on ongoing research and innovation to improve gut health worldwide.
Product StageCustomers
Evinature Takes Center Stage at AIBD Conference
growth-positive
CurQD by Evinature Found to Ease Life-Altering IBD Symptom
Evinature has published promising research on their nutraceutical product, CurQD®, which shows significant improvement in managing bowel urgency symptoms in patients with IBS and IBD. The study, published in the Journal of Crohn’s and Colitis, involved 41 participants, with 70% experiencing improvement by weeks 4 and 8. The product is also effective in pediatric cases, offering a solution for children who struggle with bowel urgency. Evinature is committed to enhancing the quality of life for its customers through personalized treatment and clinical support, aiming to reduce the frequency of symptoms and improve overall GI tract health.
Customers
growth-positive
Evinature's CurQD Successful in Pediatric Trial
Evinature has developed CurQD®, a curcumin-Qing Dai formula, which has shown promising results in reducing symptoms of mild and moderate Ulcerative Colitis (UC) and Inflammatory Bowel Disease (IBD) in pediatric patients. In a multi-center study involving 30 pediatric UC patients, 72% responded positively to CurQD®, with significant reductions in symptom severity and colon inflammation. The study highlights the potential of CurQD® as a supplemental treatment that can improve the quality of life for young patients by reducing the side effects of both the illnesses and medications. The trials success marks a significant advancement in pediatric UC treatment, offering new hope for affected children to lead more normal lives.
growth-positive
The efficacy of CurQD in children with active ulcerative colitis: a multicenter retrospective cohort study
The article discusses a study on the efficacy and safety of a combination treatment using curcumin and Qing Dai (CurQD) for pediatric patients with ulcerative colitis (UC) or inflammatory bowel disease unclassified (IBD-U) who did not respond to conventional treatments. Conducted across four pediatric gastroenterology units, the study involved 30 children and demonstrated a significant clinical response in 70% of the patients after 16 weeks of treatment. The study highlights the potential of CurQD as a safe and effective management option for pediatric UC, with minimal adverse effects reported. The treatment was produced by Evinature, a company based in Israel. The study emphasizes the need for larger prospective studies to further evaluate the clinical and endoscopic effects of CurQD in children.
growth-positive
6 Companies Making Waves in Modern Innovation
The article highlights six companies leading innovation across various industries. Substrata is transforming business interactions through its deep learning-driven social signal intelligence platform, enhancing decision-making and strategic planning. Evinature is revolutionizing the treatment of inflammatory bowel diseases with its CurQD® Protocol, developed in collaboration with Sheba Medical Center. ANYBiotics is advancing synthetic biology, creating sustainable biomaterials and chemicals. Harvestly is promoting sustainable agriculture through technology integration, improving crop yields and supporting small-scale farmers. Pet Tech is enhancing pet care with AI and smart devices, improving pet health and owner convenience. Suno is reshaping music creation with AI technology, making it accessible to a broader audience. Each company is setting new standards in their respective fields, driving positive change and innovation.
growth-positive
These are the 5 Next-Gen Startups Disrupting Their Industries - The World Financial Review
The article highlights five next-gen startups that are making significant strides in their respective industries by leveraging cutting-edge technology and innovative approaches. Evinature is advancing natural healthcare with its personalized treatments for gastrointestinal disorders. Lunar.dev is transforming API consumption management with enhanced security and cost-saving features. Fishway is pioneering sustainable seafood production through cell cultivation. Brightwheel is modernizing childcare management with its comprehensive SaaS platform. HGenium is innovating green hydrogen production with its sustainable thermochemical water-splitting technology. These startups are setting new standards and redefining industry benchmarks, showcasing the potential for transformative change.
growth-positive
6 Companies That Are Redefining Their Markets
The article discusses six companies that are redefining their respective markets through innovative products and services. Vendict is revolutionizing the cybersecurity and risk management sector with its AI-driven solutions. Gyaan is transforming the revenue intelligence market with a platform that provides actionable insights. Evinature is redefining natural health solutions by integrating scientific research with evidence-based herbal medicine. Pivot Bio is revolutionizing agriculture with microbial solutions that replace traditional fertilizers. Rockwell Automation is catering to the demand for large-scale industrial automation. CENTURY is enhancing learning in high school and college subjects by leveraging neuroscience.
CustomersPartnersInvestmentAcquisitionPublic TradingManagement ChangesLayoffsExpand
N/A
Evinature listed top among most-watched Health Tech companies in Startup Nation's H1 2024 Israeli Tech Report
The text appears to be a mix of prompts, instructions, and placeholders from a website interface, possibly related to a tech startup database or platform. It does not provide any specific information about a company, event, or issue.
N/A
growth-positive
Meet The Research Team That Broke The Therapeutic Ceiling In IBD - Healthcare Business Today
Evinature, a healthcare startup, is pioneering the integration of herbal medicine into standard clinical care. The company is dedicated to providing evidence-based, natural remedies to patients worldwide. Evinatures co-founders recently attended the Digestive Disease Week Conference where they presented their latest research on DivertX, a natural treatment for Post-Diverticulitis Syndrome (PDS). The companys research efforts, in collaboration with Sheba Medical Center, have led to the establishment of the first disease index to address unmet needs in gastroenterology. Evinatures approach is grounded in evidence and patient-centric values, promoting a holistic model of care.
CustomersPartners
growth-positive
Breaking Boundaries in IBD: Evinature's CurQD® Trial Spotlighted at the CCF’s IBD Innovate Conference 2024 | BioPharma Dive
Evinature, a healthcare startup, was invited to the 6th IBD Innovate Conference hosted by the Crohn’s & Colitis Foundation. Nir Salomon, Co-founder and Head of R&D at Evinature, presented CurQD®, a first-in-class nutraceutical for Inflammatory Bowel Disease (IBD) with high remission rates in patients failing pharmaceutical treatment. The product is available through Evinature’s platform, which facilitates direct-to-patient treatments using data-driven, tailored protocols. The conference served as a platform for knowledge exchange and collaboration among startups, innovators, researchers, and industry stakeholders.
PartnersCustomers
growth-positive
Meet the Frontmen of Evinature, the Startup That’s Revolutionizing IBD Care | The Ritz Herald
Evinature, a healthcare startup, is pioneering new technologies and therapies for the treatment of Inflammatory Bowel Disease (IBD). The companys founders, Professor Shomron Ben-Horin, M.D., Nir Salomon, and Apan Amos Damri, have developed the CurQD® Protocol, a set of natural, clinically proven regimens tailored specifically to each individual to address each stage of IBD. The protocol has been integrated into top medical centers and offers a safe and effective alternative to traditional pharmaceuticals. Evinatures platform also provides integrative strategies, guided care from a team of experts, research updates, and essential information to the community.
CustomersExpand
growth-positive
Healthcare startup Evinature is now integrated across 35 US medical centres to further streamline IBD treatment accessibility - Digital Journal
Evinature, a healthcare startup, is leading research in nutraceutical therapies for Inflammatory Bowel Disease (IBD) patients. The company has integrated CurQD as an adjunct therapy into standard care through evidence and clinical trials. This has led to collaborations with doctors in the US who have seen a demand from patients. In the past year, CurQD has been integrated into over 35 medical centres across the US as part of Evinatures aim to improve IBD treatment and patient outcomes. The company has also launched the CurQD Network, a platform that allows patients to access the CurQD Protocol through their healthcare providers.
CustomersPartners
growth-positive
Evinature: Pioneering Integrative Therapies for IBD with the CurQD® Protocol - Women's Journal
Evinature, a healthcare clinic, is leading the way in research for integrative therapies for Inflammatory Bowel Disease (IBD). The company has developed the CurQD® Protocol, a set of natural, clinically proven regimens that are highly individualized to address each stage of IBD. The protocol is now integrated into standard clinical practice in leading medical centers in Israel. Evinatures approach emphasizes the uniqueness of each patient and the dynamic nature of their conditions. The company also provides ongoing patient support, including regular follow-ups and free educational content.
CustomersExpand
Growth-Positive
Harvard Medical Professor Ashwin Ananthakrishnan Commends Evinature’s CurQD® Trial in CGH Editorial - The European Business Review
Evinature, a company focusing on integrative therapies for Inflammatory Bowel Disease (IBD), has been recognized for its CurQD® Protocol. The protocol, which combines the therapeutic properties of curcumin and Qing Dai, has been published in the Clinical Gastroenterology and Hepatology journal, sparking interest within the medical community. The companys approach to IBD treatment emphasizes the need for a holistic approach, addressing concerns about the long-term safety and potential side effects of conventional treatments. The endorsement from respected authorities like Prof. Ananthakrishnan from Harvard Medical School lends credibility to Evinatures work and signals a shift in the perception of integrative therapies.
CustomersPartners
Growth-Positive
Curcumin-QingDai Combination for Patients With Active Ulcerative Colitis: A Randomized, Double-Blinded, Placebo-Controlled Trial
A clinical trial was conducted to evaluate the efficacy of a herbal combination of curcumin-QingDai (CurQD) in treating active ulcerative colitis (UC). The study was conducted in Israel and Greece and showed positive results with CurQD inducing response and remission in active UC patients. The trial was supported by the Alan B. Slifka Foundation and a private donation from the Mousseif family. The study suggests that the aryl-hydrocarbon receptor pathway, which CurQD activates, may be a potential treatment target for UC. EviNature, a spin-off company of Sheba Center, has filed for intellectual property rights on the combination of curcumin and QD.
InvestmentPartners
growth-positive
Evinature's DivertX: A Revolutionary Natural Approach to Post-Diverticulitis Syndrome | BioPharma Dive
Healthcare startup Evinature has launched DivertX, a natural treatment for Post-Diverticulitis Syndrome (PDS). The product is designed to fill a gap in diverticulitis care, offering a preventive strategy for patients experiencing lingering symptoms after acute episodes. Evinature, known for its product CurQD®, which aids those suffering from Inflammatory Bowel Disease (IBD), has ventured into new territory with DivertX. The product combines two herbal compounds, Curcuma Longa and Coptis Chinensis, to target mucosal inflammation, bacterial imbalance, and IBS-like symptoms associated with PDS. Evinature is currently in phase 2 of their ongoing clinical trial for DivertX.
CustomersExpand
growth-positive
74-Year-Old Melissa McKown Finds IBD Relief with Evinature's CurQD® Protocol
Evinature, a pioneer in Inflammatory Bowel Disease (IBD) treatment, has developed the CurQD® Protocol, a natural treatment regime that has been integrated into standard clinical practice in leading medical centers in Israel. The company recently conducted an interview with an IBD patient, Melissa McKown, who found relief in the CurQD® Protocol after a challenging journey with ulcerative colitis. Melissas experience highlights the life-changing impact of the CurQD® Protocol on the overall well-being of IBD patients.
Customers
NCBI - WWW Error Blocked Diagnostic
The article discusses a clinical trial investigating the efficacy of a Curcumin-QingDai combination for patients with active ulcerative colitis. This study is a randomized, double-blinded, placebo-controlled trial conducted by a team of researchers including Ben-Horin S, Salomon N, and others. The trial results are published in the Clinical Gastroenterology and Hepatology journal, with the study set to appear in the February 2024 issue. The research aims to provide insights into potential new treatments for ulcerative colitis, a chronic inflammatory bowel disease.
The CurQD® Effect: IBD Patient Rafal Majorczyk Talks About His Transformative Journey With Evinature
growth-positive
Optimal Metabolism: Episode 156- NEW and Promising Nutraceutical Treatments for IBD and IBS with Nir Salomon on Apple Podcasts
Nir Salomon, director of integrative gastroenterology at Sheba Medical Center, and his research team have developed CurQD, a nutraceutical supplement designed to heal the mucosal layer of the intestines. This supplement is aimed at treating conditions such as Inflammatory Bowel Disease (IBD) and Irritable Bowel Syndrome (IBS). The podcast episode discusses the development of these nutraceuticals and their intended users. It also explores the potential for CurQD to be used in conjunction with pharmaceuticals like antibiotics or immunosuppressants.
Customers
growth-positive
A Triumph with Evinature's CurQD® Protocol: KaLeigh Castiello's Journey to Natural Remission - New York Weekly
KaLeigh Castiello, a personal trainer diagnosed with ulcerative colitis (UC), shares her journey to remission using Evinatures CurQD Protocol. After her diagnosis in 2020, Castiello explored various treatments, including conventional medication and naturopathic approaches, but found them ineffective. In 2022, she discovered Evinature and its CurQD Protocol, developed by founders Professor Shomron Ben-Horin and Nir Salomon. Within six weeks of starting the protocol, her symptoms began to recede. Today, she maintains her remission with a combination of CurQD and mesalamine, successfully avoiding the need for biologics.
Customers
growth-positive
Empowered and Informed: Evinature's Pioneering Role in IBD Patient Education | BioPharma Dive
Evinature, a healthcare company, is emphasizing the importance of patient education in managing chronic illnesses like Inflammatory Bowel Disease (IBD). The company believes that well-informed patients can improve medication adherence, reduce anxiety and depression, enhance their overall quality of life, and actively participate in their treatment plans. Evinature provides comprehensive, accessible, and up-to-date information on conditions like IBD and the latest advancements in healthcare. The company also hosts monthly webinars to educate patients about their health and well-being.
Customers
growth-positive
Evinature’s Clinic Support Introduces A New Era of IBD Patient Care - The Chicago Journal
Healthcare startup Evinature has launched Clinic Support, a customer success model that provides comprehensive patient care, including check-ins, follow-ups, adjustments, personal support, and patient/product education. The service is designed to provide a more personalized approach to treating gastrointestinal disorders, with a focus on individual patient needs and responses to supplements. The companys team is dedicated to providing emotional support and credible medical information to patients, and the service has received positive feedback from users.
Customers
growth-positive
Why Evinature is Making Lots of Noise on Reddit - Miami Wire
Evinature, an Israel-based healthcare startup, is making strides in the treatment of Inflammatory Bowel Disease (IBD) through the use of alternative medicine. The company focuses on developing and distributing nutraceuticals that have been clinically proven to help manage IBD symptoms. Their product, The CurQD Protocol, has been gaining attention on Reddit, with users sharing their positive experiences and the effectiveness of the treatment. Evinature provides its services through an online platform, making it accessible to patients worldwide.
Customers
growth-positive
A Spotlight on Apan Amos Damri, CEO of Evinature, and Their Commitment to Wellness
Evinature, a healthcare company led by CEO Apan Amos Damri, is revolutionizing the healthcare industry with innovative nutraceutical solutions. The company is focused on addressing the unmet needs in the treatment of Inflammatory Bowel Disease (IBD) by providing natural solutions. Evinature combines scientific evidence, medical expertise, patient data, and digital tools to provide accessible and effective nutraceuticals to patients worldwide. The company is also unique in that it tailors protocols for individual patients and conducts regular follow-ups, which has been shown to improve patient adherence and outcomes.
CustomersExpand
Evinature Signs Exclusive Distribution Deal with Multinational Company Adacyte Therapeutics to Expand IBD Treatment Accessibility
growth-positive
Evinature’s Curcumin-QingDai Combination Shows Promising Results to Combat IBD - LA Wire
Evinature, a startup focusing on integrative therapies for inflammatory bowel disease (IBD), has been conducting research on the use of Curcumin-QingDai in treating IBD. The company recently conducted a randomized, double-blinded, placebo-controlled trial, which showed promising results. Evinature also offers a free online assessment to help individuals discover the most effective protocol for their specific needs. The company tracks the progress of each individual and guides them through every stage with regular follow-ups and full clinic support.
Customers
Why the Increasing Global Cases of IBD Call for this Personalized and Evidence-Based Treatment
growth-positive
This Natural Medical Protocol is Revamping IBD Treatment Globally - The European Business Review
Evinature, a company specializing in natural medicine, is offering personalized treatment for patients with inflammatory bowel disease (IBD), Crohn’s, or ulcerative colitis. The company has developed the CurQD Protocol, a collection of natural, clinically-proven regimens that can be accessed from home. The protocol was developed by Professor Shomron Ben-Horin and Nir Salomon of Sheba Medical Center. The CurQD Protocol has undergone extensive testing in clinical trials and has demonstrated a high level of efficacy. The treatment process includes regular follow-ups to ensure patients are benefiting from their protocol and adjustments are made as needed.
CustomersExpand
growth-positive
Evinature exits stealth with $2 million funding to optimize global healthcare for patients with IBD, Crohn's, or Colitis through evidence-based natural remedies | BioPharma Dive
Evinature, a startup specializing in integrative therapies for IBD, has emerged from stealth mode with $2 million in funding. The funding round was led by PSC Group, with participation from Ratio technologies, Shay Livnat, and other angel investors. The Israel-based company has launched the Evinature platform, which guides patients through the CurQD Protocol, a natural and tailored treatment regime for IBD. The platform is based on the groundbreaking research of the companys founders, Professor Shomron Ben-Horin, Nir Salomon, and Apan Amos Damri. Evinature aims to integrate modern medical practice with herbal remedies and technology to provide safe, effective, and affordable medicine to people worldwide. The companys main product has been clinically proven to treat Ulcerative Colitis and has been successfully implemented into standard clinical practice in Israel. Evinatures goal is to prioritize patient accessibility to accurate medical assessments and affordable treatments.
Investment
growth-positive
How Evinature Spearheads the Gold Standard in Evidence-Based Natural Remedies for IBD, Crohn's, and Colitis
Evinature, a startup focusing on integrative therapies for gastrointestinal disorders, is aiming to bridge the gap between traditional and modern medicine. The company was founded by Nir Salomon and Professor Shomron Ben-Horin, M.D. after they confirmed the effectiveness of curcumin as a treatment for IBD. Evinature provides a patient-focused platform that offers integrative strategies, guided care, research updates, and vital information. The company emphasizes individualized treatment plans, regular patient reports, and data-driven results. It also stresses the importance of product quality and scientific integrity, distributing only products that have undergone rigorous clinical trials.
CustomersExpand
Growth-Positive
Evinature's CEO Apan Amos Damri On Providing Evidence-Based Natural Remedies to Patients with IBD, Crohn's, and Colitis | Market Analysis | NewsBreak Original
Evinature, a company specializing in integrated therapies for Inflammatory Bowel Disease (IBD), is developing and distributing clinically-proven nutraceuticals to patients worldwide. The companys goal is to provide accurate diagnosis and treatment through their proprietary online platform. Evinatures products are tested by placebo-controlled trials and are tailored to each patients condition. The companys CurQD protocol, a result of over 10 years of research, has shown exceptional results in inducing remission in ulcerative colitis patients who have not responded to pharmaceutical treatments. Evinature plans to continue developing evidence-based nutraceutical treatments for patients with chronic diseases.
CustomersExpand
Evinature Team
Summer Pitocchelli
Content Writer
Employee Info
| Employees (range) | 11-50 |
| Exact count | 17 |
| Team members | 18 |
Similar Companies
Similar companies data is computed dynamically and not stored in the entity profile. This section requires implementing a similarity query (e.g. by classification overlap, sector, district).
This entity has 8 classification IDs that could be used for matching.
Evinature Internal
Recent Updates
No update log entries.
Note: Free-text notes visible in the original Finder "Internal" tab are not present in the imported profile data. Only the update audit log is available.
Admin Info
| Confidence | 94/100 |
| Missing | markets, not claimed |
| BI Verification | Yanina Wainscheinker |
| Registrar ID | 516384070 |
| Phone | +1 (612) 261-0298 |
| Creator | Jonathan Schwartzman |
| Creator email | jonathan@evinature.com |
| Last updater | Yanina Wainscheinker |
| Updater email | yanina.wainscheinker@sncentral.org |
| Last update | 2024-06-03T00:00:00.000Z |
| Created | 2022-11-29T00:00:00.000Z |
| Claimed | Yes |